<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00250263</url>
  </required_header>
  <id_info>
    <org_study_id>Project 170/05</org_study_id>
    <nct_id>NCT00250263</nct_id>
  </id_info>
  <brief_title>A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy</brief_title>
  <official_title>A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayside Health</source>
  <brief_summary>
    <textblock>
      Allergic diseases represent a major health issue worldwide. Mainstay treatment is allergen
      avoidance and pharmacotherapy for symptom relief. Allergen immunotherapy offers the
      advantages of specific treatment with long lasting efficacy, and can modify the course of
      disease. However, use of this treatment is restricted by the high risk of adverse events
      especially in asthmatics. Other, better tolerated, routes of allergen administration than the
      current conventional subcutaneous route (SCIT) have been investigated including sublingual
      (SLIT). However, the immune parameters of SLIT have not been examined. We propose conducting
      a randomised, placebo-controlled study of a commercially-available SLIT for house dust mite
      (HDM) allergy to investigate induction of relevant T cell regulatory immune mechanisms. The
      first year will be followed by an optional open label extension period. Immunoregulatory
      cytokine synthesis and T cell phenotype and function (real time PCR and flow cytometry) will
      be examined. This project will provide important fundamental knowledge on which to base
      improved and greater application of this potentially curative treatment for allergy. SLIT has
      the potential advantage of home administration and suitability for patients with asthma who
      are currently unable to access many of the allergen desensitising regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological mechanisms of SLIT by phenotyping different subsets of cytokine positive T cells, regulatory T cells, and memory T cells in peripheral blood of subjects before, during and after immunotherapy.</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>-Expression of &quot;immunoregulatory&quot; cytokines by CD4+ T</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cells</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>- Helper, regulatory and memory T cell subsets</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(a) Helper T cells</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(b) Regulatory T cells</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>b1- Regulatory T cell phenotype</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>b2- Regulatory T cell function</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom diary, medication use, visual analogue score, disease-specific rhinoconjunctivitis Quality of Life Questionnaire</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo- control arm (first year)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug Staloral (active group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(agent for immunotherapy) Staloral</intervention_name>
    <description>Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures
Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures
Maintenance phase Day 12 to 364 - 8 pressures daily
The first year will be followed by a second year open label period (optional)- 8 pressures daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.
First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures
Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures
Maintenance phase Day 12 to 364 - 8 pressures daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allergic rhinitis and/or

          -  mild stable asthma

          -  house dust mite allergic

          -  positive HDM-specific IgE as determined by skin prick test (wheal diameter &gt;6 mm to D.
             pteronyssinus) or CAP-Pharmacia score &gt; 2

        Exclusion Criteria:

          -  Immunodeficiency diseases

          -  Severe or uncontrolled asthma

          -  Previous immunotherapy with House dust mite (HDM) extract within the last five years
             or ongoing immunotherapy with HDM or other allergens

          -  Continuous oral corticosteroids

          -  Subjects on treatment with beta-blockers

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robyn O'Hehir, MD FRACP FRCP PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alfred Hospital; Monash University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Rolland, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Alfred Hospital; Monash University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jo Douglass, MBBS FRACP MD</last_name>
    <role>Study Chair</role>
    <affiliation>Alfred Hospital; Monash University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Alfred Hospital. Department of Allergy Immunology &amp; Respiratory Medicine</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Fanta C, Bohle B, Hirt W, Siemann U, Horak F, Kraft D, Ebner H, Ebner C. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol. 1999 Nov;120(3):218-24.</citation>
    <PMID>10592467</PMID>
  </reference>
  <reference>
    <citation>Gardner LM, Thien FC, Douglass JA, Rolland JM, O'Hehir RE. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy. 2004 Aug;34(8):1209-19.</citation>
    <PMID>15298560</PMID>
  </reference>
  <reference>
    <citation>Rolland JM, Douglass J, O'Hehir RE. Allergen immunotherapy: current and new therapeutic strategies. Expert Opin Investig Drugs. 2000 Mar;9(3):515-27. Review.</citation>
    <PMID>11060692</PMID>
  </reference>
  <verification_date>November 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2005</study_first_submitted>
  <study_first_submitted_qc>November 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2005</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rhinitis</keyword>
  <keyword>asthma</keyword>
  <keyword>atopy</keyword>
  <keyword>house dust mite</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>SLIT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

